The Latest Cardiac and Vascular News
Broadens MedTech Portfolio with World Leading Solutions for Heart Recovery Strengthens Position in High-Growth MedTech Segments NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ), the world’s largest, most diversified healthcare products company, today announced it has completed its acquisition of Abiomed, Inc. Abiomed is now part of Johnson & Johnson […]
DANVERS, Mass.–(BUSINESS WIRE)–Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support at […]
NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ), the world’s largest, most diversified healthcare products company, today announced that Athos Merger Sub, Inc. (“Offeror”), a wholly owned subsidiary of Johnson & Johnson, has extended the expiration date of its offer (the “Offer”) to acquire all of the outstanding shares of […]
DANVERS, Mass.–(BUSINESS WIRE)–Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed’s newest heart pump for patients experiencing right heart failure. All three patients have now been successfully weaned off Impella support and two have already returned home with their […]
Strengthens Johnson & Johnson’s MedTech Business with the Addition of Abiomed, a World-Leader in Heart Recovery Transaction to Bring Lifesaving Innovations to More Patients with Unmet Need Expected to Enhance Johnson & Johnson’s Near- and Long-Term Sales and Earnings Growth; Accretive to Adjusted Earnings beginning in 2024 Conference Call at 8:00 […]
DANVERS, Mass.–(BUSINESS WIRE)–ABIOMED, Inc. (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announces financial results for the quarter ended September 30, 2022. Second Quarter 2023 Financial Highlights: Revenue of $266 million, an increase of 11% in constant currency, or 7% on a reported basis. This […]
DANVERS, Mass.–(BUSINESS WIRE)–Abiomed (Nasdaq: ABMD) announces that Impella RP Flex with SmartAssist has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA), the FDA’s highest level of approval, as safe and effective to treat acute right heart failure for up to 14 days. Impella RP Flex is implanted via the […]
Analysis of randomized controlled trial data shows non-Caucasian high-risk PCI patients significantly benefit from Impella-support DANVERS, Mass.–(BUSINESS WIRE)–Abiomed (Nasdaq: ABMD) announces a new program to address healthcare disparities in underserved communities, as new data provides an example of how better access to Impella heart pumps can improve health equity for non-Caucasian […]
DANVERS, Mass.–(BUSINESS WIRE)–Abiomed (Nasdaq: ABMD) announces the U.S. Food and Drug Administration (FDA) has accepted and closed the post-approval study reports related to the pre-market approvals (PMA) for Impella heart pumps. The FDA’s action is another affirmation that Impella heart pumps are safe and effective for cardiogenic shock, high-risk PCI, post-cardiotomy cardiogenic […]
Smaller Sheath Simplifies Access and Improves Ease-of-Use DANVERS, Mass.–(BUSINESS WIRE)–The United States Food and Drug Administration (FDA) has granted 510(k) clearance to Abiomed (Nasdaq: ABMD) for its Impella Low Profile Sheath. Compared to the existing 14 French (Fr) sheath used for placement of Impella CP, the new sheath maintains the same inner […]
